incidenCe and predictOrs of heaRt fAiLure After Acute coronarY Syndrome: CORALYS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-01

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Single-cohort retrospective study evaluating the incidence and prognostic markers of heart failure following acute coronary syndrome treated by percutaneous coronary intervention

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Patients Returning to Work After Acute Coronary Syndrome

NCT05145777

Acute Coronary Syndrome

UNKNOWN

Breast Cancer Long-term Outcome of Cardiac Dysfunction

NCT01904331

Breast Neoplasms

COMPLETED

Evaluation of Microcirculatory Function and Mitochondrial Respiration After Cardiovascular Surgery

NCT05330676

Shock Cardiovascular Diseases Critical Illness

COMPLETED

Outcome of Cardiac Arrest Survivors

NCT02494414

Cardiac Arrest Survivors

COMPLETED

Intra Hospital Mortality Risk Factors in Patients Admitted to Cardiac Intensive Care Units in 2017 in France

NCT03835169

Heart Disease Acute Coronary Syndrome Acute Cardiac Failure +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute coronary syndrome (ACS) is the most common cause of heart failure (HF) world-wide. Primary percutaneous coronary intervention (PCI) has deeply improved short and long-term survival after ACS, but his impact on incidence of downstream heart failure still remains unclear and heart failure after ACS represents the major driver of late morbidity, mortality and healthcare cost.

Many predictors and determinant of heart failure after MI have been evaluated, however, to date, the optimal combination of parameters to predict heart failure after MI needs to be defined and very little is known about the prognostic markers in unstable angina setting

The aim of this retrospective study:

* to show the incidence of heart failure after acute coronary artery syndrome, and the relation between the type of ACS and following incidence of HF.
* to clarify which features could be routinely identified as prognostic markers. This study is a multi-center non-randomized, single-cohort retrospective study including consecutive patients with acute coronary syndrome treated by percutaneous coronary intervention between 2017 and 2019, without known previous heart failure (baseline EF \> 40% and no medical therapy with loop diuretics), with at least 12 months of follow-up.

It is possible to anticipate that the main findings of the present study will fill fundamental knowledge gaps regarding incidence of heart failure following coronary events.

Among this, the study could suggest specific clinical and epidemiological features related to the risk of development of HF, leading to a better medical treatment and reducing risk for further hospitalizations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Informed consent

* Age ≥ 18 years
* Previous acute coronary syndrome with percutaneous coronary revascularization
* Baseline EF \> 40%
* At least 12 months of follow-up

Exclusion Criteria

* • Significant valvular heart disease (greater than mild stenosis or moderate regurgitation) before ACS

* Type 1, 3, 4, 5 pulmonary hypertension (14) before ACS
* Constrictive pericarditis before ACS
* Primary or infiltrative cardiomyopathies
* Heart transplantation
* Medical therapy with loop diuretics for heart failure before ACS
* Previous hospitalizations for heart failure or clinical sign of heart failure detected outpatient before ACS

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No